An interventional study of eCoin in Urgency Urinary Incontinence, sponsored by Valencia Technologies Corporation. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-22.
Sponsored by Valencia Technologies Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.
Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 150th largest by enrollment of the 249 interventional ones that give a count, is one of 19 that started in 2017, is one of 144 with no phase, and was the 146th registered.
988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.
Browse Urinary Incontinence studies →33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 18+ · Women only
Duke University · Sites in United States
Ages 18+ · Men only
Ohio State University · Sites in United States
Ages 18+ · Women only
The Methodist Hospital Research Institute · Sites in United States
Ages 22–80 · Men only · Healthy volunteers
University of Miami · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 23 · Phase 3 38 · Phase 4 35
First in 1993; this study’s year is marked. 19 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 66 across 743 interventional studies indexed under Urinary Incontinence.
Median enrollment 75 across the 249 interventional studies, 100 across the 43 observational. Of the 219 that completed or were terminated, 105 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 293 have an industry lead sponsor. The 10 most frequent:
Valencia Technologies Corporation is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Valencia Technologies Corporation has 4 studies filed under Urinary Incontinence — fewer than ten, so there is no comparison to draw.
16 of the studies in Urinary Incontinence with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT04565925The University of Texas Medical Branch, GalvestonSildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries | 2026-12-01 |
| NCT07534696University of California, Los AngelesEvaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy | 2026-12-31 |
| NCT06226220University of ChicagoPercutaneous Nerve Evaluation Trial Time | 2026-12-31 |
| NCT06369922University of RochesterTENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. | 2027-01-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 293 studies in Urinary Incontinence with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a single arm, prospective study of the safety and effectiveness of the Valencia Technologies eCoin System to stimulate the tibial nerve for the treatment of patients with refractory urgency urinary incontinence.
This trial is a single arm, prospective study of the safety and effectiveness of eCoin tibial nerve stimulation in 25 subjects with refractory overactive bladder as defined by the American Urological Association.. The eCoin neuromodulation device will be implanted subcutaneously in the right or left leg of patients with urgency urinary incontinence. After a 4 week implant healing period, subjects will have their devices activated (turned ON). After 3 months of device therapy (occurring 4 months post-implant), the primary endpoint will be assessed. It is anticipated that subjects will reach the full therapeutic effect at approximately 3 months of therapy. Subjects will be followed for an additional 9 months to assess the safety of maintenance stimulation therapy with fewer sessions occurring during this time interval.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment Arm receives implanted eCoin device and therapy is turned ON.
Device: eCoin
Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
Incontinent Episodes
The change in number of incontinence episodes from baseline to three months post-activation.
Time frame: Baseline to three months post-activation.
System and Procedure Related AEs
Number of System and Procedure Related Adverse Events from implantation to one month post-implantation.
Time frame: Implantation to one month post-implantation.
MAEs
Number of all Major Adverse Events from baseline to 3 months post-activation.
Time frame: Baseline to 3 months post-activation.
Percentage of Responders
Percentage of Responders, defined as participants who experienced a 50% or greater reduction in UUI after 3 months of treatment
Time frame: 3 months after activation
Participants were recruited and enrolled from April 2017 to September 2017 (i.e. 5 months). The study took place at 7 urology/urogynecology clinics across the United States and New Zealand.
| Milestone | eCoin |
|---|---|
| Started | 46 |
| Primary endpoint (3 months) | 44 |
| Completed | 41 |
| Not completed | 5 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Mri need | 2 |
The change in number of incontinence episodes from baseline to three months post-activation.
| episodes/day | eCoin |
|---|---|
| Incontinent Episodes | -3.0 ± 2.9 |
Number of System and Procedure Related Adverse Events from implantation to one month post-implantation.
| Adverse Events | eCoin |
|---|---|
| System and Procedure Related AEs | 20 |
Number of all Major Adverse Events from baseline to 3 months post-activation.
| Adverse Events | Treatment Arm |
|---|---|
| MAEs | 3 |
Percentage of Responders, defined as participants who experienced a 50% or greater reduction in UUI after 3 months of treatment
| Participants | eCoin |
|---|---|
| Percentage of Responders | 32 |
Collected over Adverse event data was collected from enrollment through 6 months after implantation.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| eCoin | 0/46 (0%) | 3/46 (6.5%) | 16/46 (34.8%) |
| Event | eCoin |
|---|---|
| Cellulitis Secondary to Ankle WrapInfections and infestations | 1/46 |
| Hip Bursitis & EdemaMusculoskeletal and connective tissue disorders | 1/46 |
| PneumoniaInfections and infestations | 1/46 |
| Event | eCoin |
|---|---|
| Moderate implant site discomfort, swelling, pain, bruisingGeneral disorders | 5/46 |
| Blister secondary to ankle wrapSkin and subcutaneous tissue disorders | 4/46 |
| Mild swelling, bruising, discomfortGeneral disorders | 3/46 |
| Possible incision site infectionInfections and infestations | 2/46 |
| Stimulation painProduct Issues | 1/46 |
| Device migration about 1 cm posteriorProduct Issues | 1/46 |
Baseline analyses includes the baseline information for enrolled and implanted participants. Data on 3 participants were imputed per protocol.
| Age, Continuous(years) | eCoin |
|---|---|
| Mean | 63.39 ± 11.5 |
| Sex: Female, Male(Participants) | eCoin |
|---|---|
| Female | 45 |
| Male | 1 |
| Ethnicity (NIH/OMB)(Participants) | eCoin |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 34 |
| Unknown or Not Reported | 12 |
| Race (NIH/OMB)(Participants) | eCoin |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 45 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | eCoin |
|---|---|
| New Zealand | 20 |
| United States | 26 |
| Urinary incontinence(episodes/day) | eCoin |
|---|---|
| Mean | 5.9 ± 3.1 |
| Urgency urinary incontinence(episodes/day) | eCoin |
|---|---|
| Mean | 5.2 ± 2.9 |
| No. OAB medication at screening(Participants) | eCoin |
|---|---|
| Count of participants | 9 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2017 to primary completion in Dec 2017, 8 months.
Results were first posted in Nov 2020, 2 years 10 months after primary completion.
Of 63 industry-sponsored interventional studies with no phase under Urinary Incontinence, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 8 months is below that.
Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Valencia Technologies Corporation